๋ฉํ์กธ๋ผ๋ฏธ๋
**๋ฉํ์กธ๋ผ๋ฏธ๋(Methazolamide)**๋ ์์ํ์์ ์ฃผ๋ก **๊ฐ๋ฐฉ๊ฐ ๋ น๋ด์ฅ**์ ๋ด๊ณผ์ ์น๋ฃ์ ์ฌ์ฉ๋๋ ๊ฒฝ๊ตฌ์ฉ **ํ์ฐํ์ํจ์ ์ต์ ์ (CAI)**์ ๋๋ค. ๊ณผ๊ฑฐ์๋ ์์(IOP)์ ๋ฎ์ถ๊ธฐ ์ํ ์ฃผ์ ์ฝ๋ฌผ์ด์์ผ๋, ํ์ฌ ์ ์ ์ฑ CAI๋ ๋๋ถ๋ถ ๊ตญ์ ์ ์์ (์: ๋๋ฅด์กธ๋ผ๋ฏธ๋, ๋ธ๋ฆฐ์กธ๋ผ๋ฏธ๋)๋ก ๋์ฒด๋์์ต๋๋ค. ๊ตญ์ ์ ์ ๋ ์ ์ ๋ถ์์ฉ ๋ฐ์๋ฅ ์ด ํจ์ฌ ๋ฎ์ผ๋ฉด์๋ ์ ์ฌํ ์์ ๊ฐ์ ํจ๊ณผ๋ฅผ ์ ๊ณตํฉ๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * **์ ์ ์ ์ํฅ:** ๊ฒฝ๊ตฌ๋ก ํฌ์ฌ๋๊ธฐ ๋๋ฌธ์ ๋ฉํ์กธ๋ผ๋ฏธ๋๋ ์ ์ ์ ํ์ฐํ์ํจ์๋ฅผ ์ต์ ํ์ฌ ๋์ฌ์ฑ ์ฐ์ฆ ๋ฐ ์ ํด์ง ๋ถ๊ท ํ(ํนํ ์ ์นผ๋ฅจํ์ฆ)์ ์ ๋ฐํ ์ ์์ต๋๋ค. * **์์์ ์ ์ฉ์ฑ:** ์ผ๋ฐ์ ์ผ๋ก ๊ตญ์ ์น๋ฃ์ ๋ฐ์ํ์ง ์๋ ๋์น์ฑ ๋ น๋ด์ฅ ํ์๋ ๊ตญ์ ํฌ์ฌ๊ฐ ๋ถ๊ฐ๋ฅํ ๊ฒฝ์ฐ์ ์ ํ์ ์ผ๋ก ์ฌ์ฉ๋ฉ๋๋ค. * **์ข ํน์ด์ ๋ฏผ๊ฐ์ฑ:** ๊ณ ์์ด๋ ๊ฒฝ๊ตฌ์ฉ CAI์ ๋ถ์์ฉ์ ํนํ ๋ฏผ๊ฐํ๋ฉฐ ์ฌ๊ฐํ ๊ธฐ๋ฉด ๋ฐ ์์ ๋ถ์ง์ ๋ณด์ผ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Methazolamide acts via noncompetitive, reversible inhibition of the enzyme **carbonic anhydrase (CA)**, specifically the **CA-II isoenzyme**. * **In the Eye (Ciliary Body):** Inhibition of CA โ reduces the formation of hydrogen (H+) and bicarbonate (HCO3-) ions from carbon dioxide and water โ decreases the availability of these ions for active transport into the posterior chamber โ **decreased aqueous humor production** โ **reduced intraocular pressure (IOP)**. * **In the Kidneys (Proximal Tubule):** Inhibition of CA โ increased renal tubular secretion of sodium (Na+), potassium (K+), and bicarbonate (HCO3-) โ **increased urine alkalinity and volume**, often resulting in a mild **hyperchloremic metabolic acidosis**. * **In the CNS:** Exhibits anticonvulsant activity independent of its diuretic effects, potentially due to localized CA inhibition in the brain or secondary to systemic metabolic acidosis.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Medical treatment of glaucoma ยท 3-4 mg/kg PO twice a day. ยท PO ยท twice a day ยท Cats may not tolerate oral carbonic anhydrase inhibitors (CAIs) as well as dogs. Reported side effects include lethargy, inappetence, vomiting. Topical CAIs may be better tolerated.
- Medical treatment of glaucoma ยท 1-2 mg/kg PO q8-12h ยท PO ยท q8-12h
- Medical treatment of glaucoma ยท 2.5-5 mg/kg PO q8-12h ยท PO ยท q8-12h
- Medical treatment of glaucoma ยท 2-4 mg/kg PO two to three times a day ยท PO ยท two to three times a day
- Medical treatment of glaucoma ยท 3-5 mg/kg divided q12h PO ยท PO ยท q12h
- Medical treatment of glaucoma ยท 2-5 mg/kg PO two to three times a day ยท PO ยท two to three times a day
- Medical treatment of glaucoma ยท 2.2-4.4 mg/kg PO two to three times a day. ยท PO ยท two to three times a day
- Medical treatment of glaucoma ยท 2-10 mg/kg PO two to three times a day. ยท PO ยท two to three times a day
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Significant hepatic disease (may precipitate hepatic coma)
- Renal or adrenocortical insufficiency
- Hyponatremia or hypokalemia
- Hyperchloremic acidosis or severe electrolyte imbalance
- Severe pulmonary obstruction (inability to increase alveolar ventilation to compensate for metabolic acidosis)
- Hypersensitivity to carbonic anhydrase inhibitors or sulfonamides
- Chronic, noncongestive, angle-closure glaucoma (long-term use may mask the condition by lowering IOP while angle closure progresses)
์ด์๋ฐ์
- GI disturbances (vomiting, diarrhea, inappetence)
- Metabolic acidosis (often manifesting as heavy panting in dogs)
- CNS effects (sedation, depression, disorientation, excitement)
- Hematologic effects (bone marrow depression, thrombocytopenia)
- Renal effects (crystalluria, dysuria, renal colic, polyuria, polydipsia)
- Hypokalemia
- Hyperglycemia
- Hyponatremia
- Hyperuricemia
- Hepatic insufficiency
- Dermatologic effects (rash)
- Hypersensitivity reactions
- Weakness or cardiac arrhythmias (secondary to electrolyte imbalances)
์ฝ๋ฌผ ์ํธ์์ฉ
- Antidepressants, Tricyclic ยท Alkaline urine caused by methazolamide may decrease excretion of tricyclic antidepressants.
- Aspirin (or other salicylates) ยท Increased risk of methazolamide accumulation and toxicity; increased risk for metabolic acidosis; methazolamide increases salicylate excretion.
- Digoxin ยท Methazolamide may cause hypokalemia, leading to an increased risk for digoxin toxicity.
- Insulin ยท Rarely, carbonic anhydrase inhibitors may interfere with the hypoglycemic effects of insulin.
- Methenamine compounds ยท Methazolamide alkalinizes urine, which may negate the urinary antiseptic effects of methenamine.
- Potassium-depleting drugs (corticosteroids, amphotericin B, corticotropin, diuretics) ยท Concomitant use may exacerbate potassium depletion and hypokalemia.
- Phenobarbital ยท Increased urinary excretion due to alkaline urine, which may reduce phenobarbital serum levels.
- Primidone ยท May result in decreased primidone concentrations.
- Quinidine ยท Alkaline urine caused by methazolamide may decrease quinidine excretion.
๋ชจ๋ํฐ๋ง
- Intraocular pressure (IOP) / tonometry
- Serum electrolytes (especially potassium and sodium)
- Blood pH / acid-base status
- Baseline CBC with differential, and periodic retests if using chronically
- Clinical signs of adverse effects (lethargy, GI upset, heavy panting)
๊ณผ์ฉ๋
Information regarding acute overdosage of methazolamide in veterinary species is limited. **Clinical Signs:** Expected signs of toxicity include severe electrolyte imbalances (hypokalemia, hyponatremia), profound metabolic acidosis, CNS depression or disorientation, and dehydration secondary to diuresis. **Management:** * Monitor serum electrolytes, blood gases (for acidosis), volume status, and CNS status. * Treat symptomatically and supportively. * Administer intravenous fluids to correct dehydration and electrolyte deficits (especially potassium supplementation if indicated). * Correct severe metabolic acidosis with sodium bicarbonate if necessary, based on blood gas analysis.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.